anonymous
Guest
anonymous
Guest
Amgen needs more true therapeutic oncology agents and they want the phase 3 PARP inhibitor that Tesaro has.
Amgen needs more true therapeutic oncology agents and they want the phase 3 PARP inhibitor that Tesaro has.